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Targeting Peptides Derived from 
Phage Display for Clinical Imaging
Supang Khondee and Wibool Piyawattanametha
Abstract
Phage display is a high-throughput technology used to identify peptides or 
proteins with high and specific binding affinities to a target, which is usually a 
protein biomarker or therapeutic receptor. In general, this technique allows peptides 
with a particular sequence to be presented on a phage particle. Peptides derived 
from phage display play an important role in drug discovery, drug delivery, cancer 
imaging, and treatment. Phage peptides themselves can act as sole therapeutics, for 
example, drugs, gene therapeutic, and immunotherapeutic agents that are com-
prehensively described elsewhere. In this chapter, we discuss phage selection and 
screening procedures in detail including some modifications to reduce nonspecific 
binding. In addition, the rationale for discovery and utilization of phage peptides 
as molecular imaging probes is focused upon. Molecular imaging is a new paradigm 
that uses advanced imaging instruments integrated with specific molecular imaging 
probes. Applications include monitoring of metabolic and molecular functions, 
therapeutic response, and drug efficacy, as well as early cancer detection, personal-
ized medicine, and image-guided therapy.
Keywords: peptides, membrane receptors, imaging, phage display, endoscopy
1. Introduction
One of the most important practices in modern era clinical imaging is imaging 
at the molecular level which can help characterize and measure in vivo biologi-
cal processes at the cellular level [1]. Thus, the technique provides unambiguous 
and  high-resolution real-time information for disease diagnoses and therapies. 
In addition, molecular imaging is usually noninvasive as a biologically active, 
 receptor-specific, targeting vector conjugated to a radioligand, nanoparticle, and/or 
fluorescent/magnetic resonance imaging (MRI) probe is administered first, and then 
the probe signals can be quantified by positron emission tomography (PET), single-
photon emission computed tomography (SPECT), magnetic resonance imaging 
(MRI), fluorescence imaging, or ultrasound. The specificity of probes may be contrib-
uted from targeting peptides, small proteins, and antibodies linked to the probes [2].
One of the most important aspects in successful molecular imaging is the devel-
opment of imaging probes. Initial efforts focused on probes that are radiolabeled 
small molecules or macromolecules, e.g., monoclonal antibodies and their frag-
ments [3]. Most such probes are unsuccessful because small molecules provide low 
specificity, whereas the antibodies have low target permeability. Taken into account 
altogether, these probes have low contrast between target tissues and background, 
leading to poor imaging qualities. Compared to small molecules and antibodies, 
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peptide imaging probes are more promising. The peptide length varies from several 
to approximately 50 amino acids [4]; thus they are usually more specific than 
small molecules and also more permeable than antibodies. The peptides have high 
capillary permeability, which allows efficient penetration into tissues. In addition, 
they also have high uptake rates in the target and rapid clearance from blood [1]. 
These distinctive advantages facilitate peptides as popular imaging probes. Such a 
probe is usually composed of a targeting peptide, a linker, and an imaging moiety. 
The linkers commonly are organic spacers, macrocyclic or branched chelators, and 
polymers, which link peptides with appropriate moieties. Different moieties render 
the probes observable by various devices, e.g., near-infrared (NIR) fluorescent dyes 
or quantum dots for optical imaging, radionuclides for PET or SPECT, and para-
magnetic agents for MRI.
Phage display technology is a powerful approach to screen for peptides with high 
affinities and specificities to biomarkers. This technology was established by Smith 
et al. in 1985 to display polypeptides on the surface of filamentous M13-derived 
bacteriophage (phage) [5]. This technique modifies the phage genome to fuse the 
deoxyribonucleic acid (DNA) encoding a peptide to a gene encoding a protein 
comprising the phage coat; thus the peptide appears on the surface of the phage. 
In this way, each phage contains a single-peptide variant and its encoding DNA 
sequence, thus retaining a genotype-phenotype linkage. A library or pool of phages 
normally contains 109–1011 peptide variants for screening. The selection procedure 
consists of three main steps: (1) panning the pool of phages on the immobilized 
biomarker, (2) removing unbound phages by washing, and (3) elution of bound 
phages. After several rounds of such selections, the peptide sequences with high 
affinities to the biomarker are determined by sequencing the encoding DNAs in the 
phages. Specificity of the peptides can be also improved by adding extra negative 
selection steps [6].
Since its inception nearly 45 years ago, phage display has been widely used in 
thousands of research papers to isolate peptides that bind various targets [7]. The 
phage peptides are labeled with imaging agents such as radioactives, fluorescences, 
and nanoparticles. These probes have been successfully used to image tumors and 
cancers [8–10]. Moreover, phage display also influenced many other scientific fields 
such as drug discovery, vaccine development, and targeted drug delivery and gene 
therapy. With advances in molecular biology, the number of disease-associated 
biomarkers at the molecular level is ever-increasing. These new discoveries are 
motivating the applications of phage display to diagnostic imaging and targeted 
drug delivery.
2. Phage biology and phage selection screening methods
2.1 Phage biology
Bacteriophages (or phages) are viruses that infect bacteria. Phage virions vary 
widely in size, shape, and complexity, and phage genomes range in size from 3.4 kb 
to almost 500 kb [11]. Most phage genomes (>95%) discovered to date are linear, 
double-stranded DNAs (dsDNAs), but there are also genomes that are single-
stranded DNAs (ssDNA), circular DNAs, and RNAs [12]. The phage genome is 
packed into a protein capsid, which together form a phage particle. Some phages, 
such as pleomorphic phages, are further covered by bacterial lipoprotein membrane 
during budding [13]. As a parasite, the phage life cycle is intertwined with that of 
the host cell, i.e., bacteria. The phage particle first attaches itself to a host cell by 
specific recognition of a receptor or other surface moiety of the host; then the phage 
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nucleic acids are inserted into the host cell. Inside the host cell, the phage genome 
shuts down defense mechanisms of the host and hijacks host cellular components 
to replicate phage genome and express capsid genes from the phage genome. 
Eventually, phage genomes and capsids are assembled into progeny phage particles. 
These phage particles emerge from the host cell, which usually results in cell lysis by 
phage proteins (Figure 1).
Phages were discovered by Twort in 1915 and d’Hérelle in 1917 [12], respectively. 
Now, it is clear that phages are the most abundant organisms on the earth; they 
have been found in every environment with bacteria. An estimated 1031 phage 
particles exist on earth. Since the 1940s, phages have been model organisms and 
have contributed to molecular biology substantially. The most remarkable contribu-
tions include revealing the random nature of mutation, the discovery of DNA as the 
genetic material, and the understanding of gene expression control. With advances 
in biotechnology, phage display was established by Smith in 1985.
In phage display, the most widely used phage is the M13 strain of filamentous 
bacteriophage. This type of phage infects F plasmid-containing gram-negative 
bacteria, such as Escherichia coli. Besides M13, other members of filamentous phages 
such as f1 and fd strains have also been used for phage display [14]. These phages 
have circular single-stranded DNA (ssDNA). The genome is composed of 11 genes 
[15], which are classified into three groups by functions. The first group comprises 
Figure 1. 
A scheme presents lytic and lysogenic stages of phage.
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capsid proteins: protein III (pIII), pVI, pVII, pVIII, and pIX; the second group is for 
DNA replication, pII, pV, and pX; the last group consists of proteins for assembly, 
pI, pIV, and pXI. This genome is contained in a protein coat to form a phage particle 
of 6.5 nm in width and ~900 nm in length. Normally, filamentous phage is not lytic; 
thus phages are released from bacteria without bacterial lysis. Instead of phage M13, 
phage display can also use phagemid, which is simply a plasmid with a phage origin 
of replication so that the plasmid can be replicated and packaged into phage par-
ticles. The phagemid as a cloning vector needs helper phage to complete its infection 
process and virion packaging [16].
2.2 Phage selection screening methods
2.2.1 Peptide library
Peptide library construction is the first step in selecting peptides with high affini-
ties to the target of interest. Each of the 20 amino acids is encoded by codons, and 
each codon consists of three consecutive nucleotides. There are four types of nucleo-
tides, denoted as A (adenine), G (guanine), C (cytosine), and T (thymine). A random 
peptide is constructed by synthesizing an oligonucleotide containing (NNK)n, where 
N stands for any of the four nucleotides, K stands for either G or T, and n indicates the 
desired length of the peptide. Note that only G or T is introduced to the third position 
of a codon because this reduces the frequency of stop codons (NNN generates three 
stop codons: TAA, TGA and TAG, whereas NNK generates only one codon: TAG). To 
add a site with N, simply provide an equimolar mixture of A, T, G, and C, and 
randomly one of them is added at the end of the nucleotide chain. As for a site with K, 
just provide a mixture of G and T to the reaction [17]. In this way, numerous oligo-
nucleotides are synthesized in parallel, and each oligonucleotide encodes a random 
peptide. Note that the NNK codon pattern is generated by controlling nucleotide types 
to be added in reactions. This simple rule can be modified to create particular codons, 
e.g., allowing no stop codon or creating codons of charged residues.
Peptide libraries often have short peptide lengths, approximately less than 50 
residues. The optimum length required for the randomized displayed peptide is often 
unknown before selection and varies with many factors including the folding proper-
ties of the displayed peptide and the target of interest. For a library of random pep-
tides with seven residues, the maximum number of different peptides is 207. However, 
this number is usually unapproachable due to codon degeneracy and early stop codon. 
In other words, a library usually contains redundant peptides and peptides shorter 
than desired. On the other hand, the capacity of selection is limited by transfection, 
i.e., only 108–1010 phages, each encloses one peptide, can be transformed into E. coli 
by electroporation or other techniques. Taken together, the diversity of a library is 
important for the success of selection and screening for high affinity peptides. A typi-
cal commercially available library archives peptide diversity at the level of 109 [4].
In M13 phage, the oligonucleotides encoding random peptides are mostly fused 
to the N-terminus of pIII, with a spacer as a linker to generate a phage library. 
Another widely used gene for peptide display is the one encoding pVIII. Both 
pIII and pVIII are the major and minor capsid proteins, accessible from the outer 
surface of the phage. pIII has 406 residues, and for each phage, there are in total 
3–5 pIII proteins which form a knob-like structure at one end of the phage. This 
structure is responsible for infection of bacteria via the F-pilus, virion stability, 
and assembly termination. The peptides linked to pIII for display almost have no 
restriction on length, facilitating pIII as the mostly targeted for peptide display 
applications. As for pVIII, it is a short helical protein (50 residues) [18], and about 
2700 pVIII molecules are present on the capsid. However, only the three residues 
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at the N-terminus are accessible from the outer surface of the phage. Unlike pIII, 
pVIII can tolerate only short peptides with less than ten residues to be linked and 
successfully displayed, which is likely due to interrupted assembly by long peptides. 
However, this problem can be alleviated by reducing the density of pVIII mutants 
[19]. Interestingly, some other capsid proteins such as pV1, pVII, and pIX have 
poorer accessibilities on the phage surface but nevertheless successfully display 
peptides for screening [19].
2.2.2 In vitro screening
In a phage library, each of the trillion phages displays a single variant of random 
peptides on its surface. Many methods have been developed to identify the peptides 
that have high affinities to the target of interest, e.g., a biomarker protein. To this end, 
biopanning is the most commonly used method, and it has many variations to improve 
the performance of selection and screening or to accommodate for special targets [20].
Biopanning consists of four basic steps: (i) target immobilization, (ii) phage 
binding, (iii) washing, and (iv) phage elution. In the first step, the target of interest 
is purified and immobilized on plates. Some targets are not able to maintain struc-
tural integrity after being separated from cells, e.g., some transmembrane proteins. 
Therefore, whole cells or engineered cells may instead be immobilized on plates or 
suspended in solutions in this step [21]. In phage binding, the phages in a library 
are incubated with the plate, and appropriate buffers are also added to facilitate 
the binding reactions between the displayed peptides on phages and the targets on 
plates. After that, the plates are washed to remove unbound phages. Phage elution 
is to acquire the bound phages by disrupting the interaction between the peptides 
and the targets. This disruption is conducted by changing pH or adding compet-
ing ligands, denaturant, or protease. The eluted phages are amplified by infecting 
E. coli. The phages may go through another round of biopanning or are subject to 
DNA sequencing to determine the peptide sequences (Figure 2). These peptides are 
considered to possess high affinities to the target.
Following several rounds of biopanning, the selected peptides have high affini-
ties to the target but may not have high specificities, i.e., the peptides may also bind 
to nontargets with high affinities. To this end, subtractive screening can be added 
to the basic biopanning steps. The subtractive strategy allows phages to interact 
with nontargets, and thus the unbound phages are candidates that are specific to 
the target of interest. For example, to identify the peptides that specifically bind 
to esophageal cancer cells, Zhang et al. use normal human esophageal epithelial 
cells as the nontarget to perform subtractive screening, followed by screening 
against esophageal cancer cells. They repeated this procedure for three rounds and 
discovered two peptides that exhibited higher binding affinities and specificities 
for the cancer cells, which were validated by enzyme-linked immunosorbent assays 
(ELISAs), immunofluorescence assays, and immunohistochemistry assays [6].
Improvement of peptide library screening could be performed through small 
modifications. A stepwise reduction of elution buffer pH in the final round of 
biopanning reduces low affinity phages, thus effectively further enriching for high 
affinity phages. Optimized commercial kits are also available, for example, solid-
phase screening, solution-sorting screening, kinetic antibody binding screening, 
and capture-sandwich ELISA screening [22, 23].
2.2.3 In vivo screening
In vivo screening of phage display is designed to isolate tissue-specific binders 
in living animals. Unlike in vitro screening, this in vivo approach considers the 
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complexity and heterogeneity of the living organism and thus is one step closer to 
clinical applications. The phage library is administered directly into a living animal 
and allowed to circulate for a period of time, and then the animal is sacrificed with 
the desired organ extracted and homogenized in saline. The lysates or pelleted cells 
of the organ are used to infect E. coli so that the phages with high-affinity binding 
peptides are amplified. This procedure is repeated several rounds, and the resul-
tant phages are sequenced to determine the binding peptide sequences. Similar to 
in vitro screening, in vivo screening can have a step to wash away unbound phages. 
It is achieved usually by perfusion of the left ventricle of the animal with saline [24].
In vivo screening faces a more complicated environment than in vitro screening 
and thus requires extra considerations. Filamentous bacteriophages are often used 
for in vitro screening; however these viral particles are quite long (>500 nm) and 
thus may have problems during extravasation to some tissues. For example, M13 
phage cannot be used to target liver parenchymal cells due to the impermeability 
problem [25]. Instead, T7 bacteriophage is used to identify peptides targeting livers 
because it is smaller in size. An even more challenging issue for in vivo phages is 
how to avoid immune surveillance for accurate phage displays. Host immune sys-
tem, particularly reticuloendothelial system, degrades phages quickly and increases 
nonspecific uptake in the liver and spleen. As expected, the severity of these 
phenomena reduces within immune-compromised nude and SCID mouse strains. 
Glycosylation and succinylation to wild-type M13 phages substantially reduce its 
half-life in murine bloodstream from 4.5 hours to 18 and 1.5 minutes, respectively 
[26]. This indicates that phages modified to display peptides should have a similarly 
short half-life, which is consistent with existing data. Therefore, the optimal time 
of phage library circulation needs to be determined before the actual in vivo phage 
display experiments. The time varies with phage modifications and targeted tissues.
Phage library administration is another concern for in vivo screening. 
Administration approaches determine circulation routes of phages in living animals. 
Figure 2. 
General scheme of affinity selection of target-specific peptides.
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The most widely used approach is intravenous delivery. It enables rapid exposure of 
the phages to vascular receptors of any organ or tissue. However, this approach is inap-
propriate to the discovery of peptides targeting brain tissues due to the blood-brain 
barrier. To this end, Wan et al. administered phage library intranasally and identified a 
peptide targeting the brain, which performs 50-fold better than random control pep-
tides. Other “bloodless” approaches including site-directed phage administrations and 
transdermal delivery have been used successfully to identify targeting peptides [27].
3.  General considerations for phage display to target membrane 
receptors
Membrane proteins are the most popular targets for diagnostic and therapeutic 
applications. The structures of membrane proteins are generally composed of three 
parts, i.e., the extracellular, transmembrane, and intracellular domains. The extra-
cellular domains are the primary targets of drug discovery and diagnosis. About 
60% of drug targets are membrane proteins [28]. More specifically, membrane 
proteins are targeted by the 61% monoclonal antibodies approved or under review 
as therapeutic drugs throughout Europe and the United States. This prevalence is all 
attributed to the unique properties of membrane proteins. First, they have various 
important biological functions such as in signaling and cell channels; thus drugs 
targeting them can manipulate cellular functions effectively. Second, membrane 
proteins are presented on cell surface and thus are more accessible than cellular 
proteins. Some membrane proteins can define cell types. For example, various 
cluster of differentiation (CD) markers are membrane proteins and define immune 
cell types. More importantly, diseases usually alter expression levels of membrane 
proteins. A well-known example is the overexpression of human epidermal growth 
factor receptor 2 (HER2) membrane protein in 20-25% of breast cancers.
Despite being popular targets, membrane proteins present a limitation for phage 
display. The key to a successful phage display is the presentation of correctly folded 
targets, i.e., native structures of extracellular domains (ectodomains) in membrane 
proteins. This is fairly easy for soluble proteins because they fold correctly in solution 
while being immobilized on a surface, whereas membrane proteins usually fail to 
fold into their native structure in solution without membranes [29]. For example,  
G protein-coupled receptors (GPCRs) constitute the largest class of drug targets but 
have had limited success in phage display due to their hydrophobic regions and com-
plicated ectodomains, which are usually comprised of the N-terminal chain, parts of 
the seven transmembrane helices, and their connecting loops. To stabilize the mem-
brane proteins, several methods have been developed. The principle of this method 
is to engineer the membrane proteins by mutations or adding hydrophilic domains so 
that they maintain stability in solution for phage display. Note that such engineering 
must not interfere with the native fold of the ectodomain of membrane proteins.
Another way to circumvent the limitation of unstable membrane proteins in solu-
tion is directly biopanning on whole cells instead of immobilizing membrane proteins 
on a surface as targets for phage display screening. Although this whole cell panning 
provides membrane proteins in native state as screening targets, it causes extra dif-
ficulties. First, the membrane protein may be present at low density on the cell surface; 
thus other nontargeted membrane proteins generate a high background noise. Second, 
other components on the surface of cells, such as sugar or lipid polymers, may seques-
ter phage particles for nonspecific uptake into a cell. Taken together, both of these 
possibilities facilitate the selection of nonspecific ligands, rendering phage display 
inefficient. To address these newly introduced problems, Jones et al. have reported a 
modified phage display screening for antibodies. The key innovation is that the cell is 
Bacteriophages - Perspectives and Future
8
transfected so that the target membrane protein and green fluorescent protein (GFP) 
are highly expressed simultaneously. For phage display, the green fluorescence provides 
a means to select only the cells with the target membrane protein highly expressed on 
cell surface using fluorescence-activated cell sorting (FACS) [29]. In other steps of 
phage display, small but nontrivial modifications are also adopted to improve or over-
come the problems of using whole cells. For example, a low pH wash is found effective 
in removing phage that is present through nonantibody binding. Details of these many 
small modifications in phage display protocols are reviewed by Alfaleh et al. [30].
A third category of methods has also been developed to create cell membrane-
like microenvironments that preserve the stability and integrity of membrane 
proteins for phage display. In the first method, the membrane protein is purified 
in the presence of detergents, which forms micelles after exceeding their critical 
micellar concentration. These micelles mimic cell membrane and have been used 
in phage display to identify antibodies to the sodium-citrate cotransporter and 
the fluoride ion channel. However, detergent micelles themselves are unstable and 
heterogeneous in size, which may cause membrane proteins to unfold or aggregate. 
In another method, the membrane protein is inserted into a liposome, which is 
a bilayer structure that more closely mimics the cell membrane than detergent 
micelles. Recently, nanodiscs and virus-like particles (VLP) have been developed to 
mimic host membrane protein. Nanodiscs are macromolecular structures that spon-
taneously assemble when lipids and apolipoprotein A1 or B are mixed. In general, 
one nanodisc structure contains a lipid bilayer of ~1000 phospholipids bundled by 
two apolipoproteins. The diameter of a nanodisc is ~10 nm and thus houses only 
one membrane protein approximately. Nanodiscs can take in a membrane protein 
through coupled in vitro transcription-translation. A VLP contains viral capsid 
proteins, lipids, and membrane proteins on its surface, but not a viral genome. It is 
much more stable than native cells, micelles, and liposomes and thus can withstand 
wash buffers with detergents, which decreases nonspecific binding in phage display.
In summary, some simple ectodomains of membrane proteins can be directly 
immobilized on plastic surfaces and treated as soluble proteins in phage display, 
whereas some other membrane proteins need to be engineered to increase ectodo-
main stability and integrity before phage display. Various nanoparticles such as 
detergent micelle, nanodisc, and VLP have been developed to create membrane-like 
environments to house membrane proteins. Panning directly on wild-type cells or 
on engineered cells, e.g., with membrane proteins highly expressed, is another way 
to represent membrane proteins for phage display. Such methods have to manage 
high background noise from cells. However, these methods have a unique advan-
tage, i.e., consistent with native binding mechanisms. Many membrane receptors, 
e.g., cytokine receptors, exert their biological functions through ligand binding and 
dimerization. The ligand may interact with the monomer first and then mediate 
dimerization for function or bind to the dimer directly and then carry out its func-
tion. These two scenarios may both occur depending on the ligand concentrations 
[31]. Therefore, in those methods without whole cells, the monomer immobilized 
in phage display may not mimic the targets in vivo, and thus the ligand selected by 
phage display may not bind to in vivo receptors with high affinities.
4. Phage display provides potential therapeutic and diagnostic agents
Peptide phage display has played an important role in the development of 
clinically useful therapeutics and diagnostic agents. Peptide-based therapeutics 
have attracted a significant level of interest in the drug discovery and development 
industry. First, phage particles themselves can be used as the therapeutic agent. For 
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example, the M13 bacteriophage was used successfully to treat a bacterial infection 
by delivering DNA encoding for bactericidal toxin proteins [32].
Second, peptides derived from phage display can be used as therapeutic drugs. 
In 2017, peptide drug annual market was approximately $300–500 million and is 
estimated to increase 25% each year [33]. Compared to proteins and antibodies, 
peptides have numerous advantages, for example, low manufacturing costs, better 
activity and stability, negligible immunogenicity, and superior organ penetration. 
A number of peptide drugs developed from phage display technique have been 
approved or are currently in clinical trials. For example, DX-890, an inhibitor of 
human neutrophil elastase, with potential application in the treatment of pulmo-
nary diseases such as cystic fibrosis and chronic obstructive pulmonary disease, was 
originated from phage display [34]. Ecallantide, a highly potent inhibitor of human 
plasma kallikrein, has been approved by the US Food and Drug Administration for 
the treatment of acute hereditary angioedema [35].
Filamentous phage has also been used as an immunogenic carrier useful in vac-
cine development, with high immunogenicity, low production cost, and high stabil-
ity. In addition, phage can also act as a gene-delivery vehicle. For example, phage can 
deliver functional genes to mammalian cells through receptor-mediated endocytosis.
Phage-derived peptides that bind protein targets with high affinity and specific-
ity can be used as molecular imaging probes. The classic example is octreotide, an 
eight amino acid cyclized peptide that binds the somatostatin receptor. 111In-DTPA-
octreotide (OctreoScan®) has been used successfully to image somatostatin 
receptor-positive tumors in humans [36].
5.  Applications of targeting peptides derived from phages in clinical 
imaging
Targeted molecular imaging of disease processes, particularly tumor growth 
and metastasis, has been a focus of many investigations recently. Molecular imag-
ing probes have assisted in the understanding of fundamental biological processes, 
disease pathologies, as well as pharmaceutical development. Enormous progress 
has been made in both discovery of imaging probes and development of imaging 
instruments. Additionally, optical imaging methods provide many advantages over 
other imaging modalities that include high sensitivity, the use of nonradioactive 
materials, and safe detection using readily available instruments at moderate cost. 
Today, in vivo imaging can be applied at preclinical and clinical settings due to sig-
nificant improvements in engineering technologies, optical systems, and advanced 
imaging instruments. These technologies in a combination with cutting-edge opti-
cal imaging probes provide noninvasive, real-time imaging at macroscopic and cel-
lular levels. Indeed, the combination of numerous NIR probes and targeted ligands, 
such as antibodies, aptamers, and engineered peptides, has significantly enhanced 
the performance of optical imaging systems. Recent progress in clinical imaging 
and the utilization of phage-derived targeting peptides are reviewed below.
5.1 Magnetic resonance imaging
MRI is a medical imaging technique used in radiology to form pictures of the anat-
omy and the physiological processes of the body, including in healthy and diseased 
tissues and organs. MRI scanners use strong magnetic fields, electric field gradients, 
and radio waves to generate images of the organs in the body. After a radiofrequency 
pulse, MRI detects the relaxation times of magnetic dipoles, such as hydrogen atoms in 
water and organic compounds, and generates MR signals. MRI offers spatial resolution 
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on the millimeter scale with simultaneous physiological and anatomical correlation. 
However, MRI requires long scan and postprocessing times and has relatively low 
sensitivity, thus requiring high doses of magnetic contrast agents.
In a reparative or reactive process, excess fibrous connective tissue (type I 
collagen) or fibrosis could be formed in a tissue. This is a common consequence 
in many chronic heart, kidney, liver, lung, or vasculature diseases. The high levels 
of collagen in fibrosis make it an attractive MRI target. Therefore, a collagen-
specific MRI contrast agent was developed. A type I collagen-specific peptide was 
identified using phage display and subsequently modified to improve affinity for 
collagen. Conjugate EP-3533 consists of a peptide of 16 amino acids, with 3 amino 
acids flanking a cyclic peptide of 10 amino acids that is formed through a disulfide 
bond. The peptide was modified with biphenylalanine and gadolinium to improve 
collagen binding and sensitivity. EP-3533 was evaluated in a mouse model of aged 
myocardial infarction. From MR images, EP-3533 was able to enhance the collagen-
rich scar, providing specific, high-contrast images compared to adjacent viable 
myocardium tissues and blood vessels [37].
Another example of the utilization of peptides from phage with MRI in 
early detection of colorectal cancer (CRC) was reported. Human gastric mucin 
(MUC5AC) is secreted in the colonic mucus of cancer patients. MUC5AC is a specific 
marker of precancerous lesions called aberrant crypt foci. MRI can detect the accu-
mulation of MUC5AC in xenograft and mouse stomach. To enhance MRI visualiza-
tion, peptides that specifically bound MUC5AC were developed using an M13 phage 
library. Once, the peptide binding MUC5AC (C-PSIYPLL-C, 60C) was identified; it 
was synthesized and conjugated to biotin and finally to ultra-small particles of iron 
oxide (USPIOs). The ability of USPIO-60C to detect MUC5AC in vivo was inves-
tigated on two xenograft mouse models. A heterogeneous but significant negative 
enhancement was observed in MUC5AC-secreting tumor postcontrast images 1 hour 
after intravenous USPIO-60C administration [38]. The results provided in this study 
supply a proof of concept that targeted contrast agents can be used to detect pathol-
ogies earlier than allowed by conventional MRI approaches or clinical assessment.
5.2  Positron emission tomography/single-photon emission computed 
tomography
PET and SPECT are nuclear medicine tomographic imaging techniques using 
gamma (γ) rays. Both techniques require the injection of a radioactive tracer. There 
are three main tracers used in SPECT imaging: technetium-99m, iodine-123, and 
iodine-131. The radioactive tracer emits gamma rays from the patient. PET and 
SPECT record high- and low-energy γ-rays emitted from within the body. These 
imaging modalities have very high sensitivity but relatively low spatial resolution.
VRPMPLQ (VQ ) is a heptapeptide sequence first identified by Hsiung and 
colleagues by screening phage display peptide libraries against fresh human colonic 
adenomas [39]. In a later study, Shi and team synthesized and evaluated 99mTc-
HYNIC-VQ (HYNIC 5,6-hydrazinonicotinamide) as a SPECT radiotracer for tumor 
imaging in five different xenograft mouse models (HT-29 human colon cancer, 
CL187 human colon cancer, BGC823 human gastric cancer, U87MG human glioma, 
and UM-SCC-22B human head and neck cancer). The images were acquired 1 and 
2 hours postinjection. The tumors were clearly visualized at 1 hour postinjection 
with excellent target-to-background (T/B) contrast. The studies demonstrated that 
99mTc-HYNIC-VQ could provide high-contrast images in different tumor models 
and an inflammation model [40].
In another study, a radioactive probe targeted to a dysplastic lesion in inflam-
matory bowel disease (IBD) or early CRC was developed. The cyclic peptide 
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c[Cys-Thr-Pro-Ser-Pro-Phe-Ser-His-Cys]OH (TCP-1) was originally identified in 
an orthotopic mouse CRC model using phage display selection [41]. TCP-1 peptide 
was labeled with radioisotope technetium-99 m (99mTc) and the NIR fluorophore 
cyanine-7 (Cy7) for molecular imaging. The in vivo images of 99mTc-TCP-1 in 
xenografted HCT116 and PC3 prostate cancer models were collected using dynamic 
or static SPECT. The 99mTc-TCP-1 or control peptides were administered via intra-
venous or tail vein injection. Dynamic images of 99mTc-TCP-1 in HCT116 colon 
cancer xenograft mice exhibited that the tumor could be detected in 15–30 minutes 
after injection and remained visible until 180 minutes. The data demonstrated the 
feasibility of TCP-1-targeted detection of colorectal tumor [42].
5.3 Photoacoustic tomography
Photoacoustic tomography (PAT) is an emerging imaging technique that 
demonstrates great potential for preclinical research and clinical applications. PAT 
is a hybrid system that detects the acoustic energy of endogenous chromophore or 
exogenous contrast agent optical absorption. PAT generates high-resolution images 
in both the optical ballistic and diffusive regimes due to less ultrasound scatter 
in tissue. Over the past decade, the photoacoustic technique has been developing 
rapidly, leading to exciting findings and applications.
Epidermal growth factor receptor (EGFR) is highly overexpressed in hepatocel-
lular carcinoma (HCC). Therefore, it is a potential cell surface molecule for in vivo 
targeted imaging of HCC. A peptide specific for EGFR previously reported by Zhou 
and team was conjugated to Cy5.5 dye. Nude mice were injected with EGFR overex-
pressed human HCC cells. A 2D ultrasound scanner and MRI system were used to 
monitor tumor growth in the mice. Cy5.5-labeled EGFR and control peptides were 
injected to the mice separately. Photoacoustic images were recorded periodically for 
24 hours. At 3 hours postinjection, the maximum photoacoustic signal in tumors 
was seen and results in high-contrast images of tumors beneath the skin. The T/B 
ratio was significantly different between the EGFR and control peptide. The signal 
was diminished by 24 hours [43]. From the data, a peptide specific for EGFR can 
detect HCC xenograft tumors in vivo with photoacoustic imaging.
5.4 Optical endomicroscopy
Optical imaging offers several unique advantages. Optics is nonionizing and 
provides resolution on the micron scale. Another advantage of optical imaging is 
the ability to collect images in real time in comparison to other imaging modalities, 
such as MRI and PET.
Endoscopes are thin, flexible instruments that provide a macroscopic view of the 
large mucosal surfaces in hollow organs internal to the human body. Endomicroscopy 
employs high numerical aperture (NA) optics to provide a small field-of-view (FOV) 
with micron-level resolution for observing subcellular features. It commonly requires 
scaling down the size of a conventional microscope design into a miniature package. 
Novel optical designs and scanning mechanisms have been developed to improve 
imaging performance for both endoscopy and endomicroscopy. These instruments 
provide a unique opportunity for early cancer detection and prevention by allowing 
biopsy or resection to be performed concurrently with diagnosis.
5.4.1 Wide-field fluorescence endoscopy
Previously, all CRCs were believed to arise from adenomas that progress through 
the traditional adenocarcinoma sequence. Recently, this pathway has been found 
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to account for approximately 60% of CRCs, and up to 35% are now attributed to 
the serrated pathway [44]. White-light endoscopy (WLE) that is normally used 
in colonoscopy is sensitive to gross morphologic abnormalities, such as polyps. 
Dysplasia that is flat in morphology, focal in size, and patchy in distribution appears 
“invisible” on conventional wide-field endoscopy. Therefore, imaging methods 
with improved contrast and sensitivity to molecular rather than morphological 
properties that could improve early detection and prevention of CRC are in needed. 
There are several reports on discovery and validation of targeted peptides derived 
from phage display for early detection of CRC [45].
One group used phage display to identify a peptide that binds to dysplastic 
colonic mucosa in vivo in a genetically engineered mouse model of colorectal 
tumorigenesis, CPC;Apc [46, 47]. A peptide, QPIHPNNM, was isolated after 
several rounds of in vivo T7 library biopanning. The peptide was synthesized, fluo-
rescently labeled, and purified. The peptide was sprayed topically in mouse distal 
colon. The wide-field fluorescent videos were recorded. After quantitative image 
analysis, the fluorescent-labeled peptide was significantly bound twofold greater 
to the colonic adenomas when compared to the control peptide. The target peptide 
also showed minimal binding to an activated KrasG12D mutant mouse model that 
demonstrates hyperplastic polyp-like features used as a control hyperplastic model 
that does not progress to carcinoma (Figure 3A) and the lumen of a CPC;Apc bred 
mouse negative (Figure 3B).
c-Met overexpression has been shown to occur as an early event in colorectal 
adenocarcinoma. A peptide that has high affinity for the extracellular domain 
of human c-Met was discovered using an M-13 phage display library. GE-137 is 
a water-soluble cyclic peptide (AGSCYCSGPPRFECWCYETEGT) labeled with 
a cyanine dye with a high affinity for human c-Met. The quantitative biodis-
tribution, pharmacokinetics, binding specificity, and qualitative fluorescence 
of GE-137 were assessed in a CRC xenograft mouse model using subcutaneous 
injection of the c-Met-expressing human CRC cell line HT29. Intravenously 
administered GE-137 accumulated in the c-Met-expressing tumor xenografts 
and left a fluorescent signal in the tumors and kidneys 120 and 240 minutes 
Figure 3. 
Images from wide-field endoscopy videos after topical application of fluorescence-labeled peptides. The top and 
bottom panels represent frames from white light and fluorescence, respectively. (A) The hyperplastic epithelium 
after QPI peptide application, (B) the lumen of a CPC;Apc bred mouse negative for Cre recombinase (control 
litter mate), (C) single adenoma after control peptide application, (D) single adenoma, and (E) multiple 
adenomas in a CPC;Apc mouse after QPI peptide application. Used with permission [47].
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after injection (Figure 4). In a pilot study in 15 patients at high risk of colorectal 
neoplasia, a total of 101 lesions were detected during first inspection with white 
light (WL), and an additional 22 were detected during second inspection with 
dual WL/fluorescence (FL). After immunohistochemical analysis, 36 hyperplas-
tic lesions and 8 serrated polyps were identified. Most of these were visible in 
fluorescent mode (94 and 100%, respectively), and the majority (78 and 87%, 
respectively) showed increased fluorescence. From the data, GE-137 peptide 
showed some specificity to hyperplasia and serrated lesions in CRC mouse model 
and patients [48].
Overexpression of EGFR has been reported in as high as 97% of colonic adeno-
carcinomas, and it is a validated biomarker for CRC. In one study, the extracellular 
domain of EGFR (EGFR-ECD) was expressed and purified [49]. A library of 
M13 bacteriophage was used to select peptide candidates that bind specifically to 
EGFR-ECD. A peptide, QRHKPRE, that is specific for EGFR was developed and 
validated. Peptide binding to cells occurred within 2.46 minutes and had an affin-
ity of 50 nM. A NIR fluorescence endoscope was used to perform in vivo imaging 
to validate peptide binding to spontaneous colonic adenomas in a CPC;Apc mouse 
model via topical administration (Figure 5). T/B ratios of polyps and flat lesions 
were 4.0 ± 1.7 and 2.7 ± 0.7, respectively. Subsequently, specific peptide binding to 
human colonic adenomas was assessed on immunohistochemistry and immuno-
fluorescence. On human colonic specimens, greater intensity from peptide binding 
to dysplasia than normal was found with a 19.4-fold difference.
In another study, a phage-derived peptide was tested for specific binding to 
sessile serrated adenomas (SSAs) in proximal colon which accounts for 35% in 
CRC. Joshi and team used phage display to identify a peptide that binds specifically 
to SSAs. Many SSA cells have the V600E mutation in BRAF. Therefore, peptide 
selection was performed with an M13 Ph.D.-7 phage display library using a biopan-
ning strategy with subtractive hybridization with HT29 colorectal cancer cells 
containing the V600E mutation in BRAF [45]. Binding of fluorescently labeled pep-
tide, KCCFPAQ , to colorectal cancer cells was evaluated with confocal fluorescence 
Figure 4. 
WL and FL images of representative lesions. (a–c) The lesions that are visible in WL show increased 
fluorescence. (d) A lesion that is visible in WL has enhanced visibility in FL. (e, f) Flat lesions that were only 
visible in FL. Used with permission [48].
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microscopy. The peptide showed an apparent dissociation constant of Kd = 72 nM 
and an apparent association time constant of K = 0.174/minute. Toxicity was also 
assessed in rats. In the clinical safety study, fluorescently labeled peptide was 
topically administered, using a spray catheter, to the proximal colon of 25 subjects 
undergoing routine outpatient colonoscopies. Subsequently, endoscopists resected 
identified lesions, which were analyzed histologically by gastrointestinal patholo-
gists. Fluorescence intensities of SSAs were compared with those of normal colonic 
mucosa. During fluorescence imaging of patients during endoscopy, regions of 
SSA had 2.43-fold higher mean fluorescence intensity than that for normal colonic 
mucosa. Fluorescence labeling distinguished SSAs from normal colonic mucosa 
with 89% sensitivity and 92% specificity.
5.4.2 Confocal laser endomicroscopy
Confocal laser endomicroscopy (CLE) is an endoscopic modality that based 
on tissue illumination using a low power laser and the subsequent detection of 
fluorescent light that is reflected back from the tissue through a pinhole. The term 
“confocal” refers to the alignment of both illumination and collection systems in 
the same plane. This alignment dramatically increases the spatial resolution of CLE 
and enables cellular imaging and evaluation of tissue architecture at the focal plane. 
CLE can be used to guide biopsies and has been demonstrated in a number of clini-
cal studies to detect cancer in the digestive tract, bladder, cervix, ovary, oral cavity, 
and lungs. CLE requires the use of a fluorescent contrast agent to enhance visu-
alization of cells. Contrast agents can be administered intravenously or topically. 
Intravenous fluorescein sodium and acriflavine are widely used contrast agents. 
Figure 5. 
In vivo imaging of colon in CPC;Apc mouse. (a) WL image of colon in CPC;Apc mouse shows the presence 
of polyp (arrow). (b) NIR fluorescence image after topical administration of QRH*-Cy5.5 shows increased 
intensity from polyp (arrow) and several flat lesions (arrowheads). (c) Image with Cy5.5-control peptide 
(PEH*-Cy5.5) shows minimal signal. (d) WL image shows no grossly visible lesions (polyps). (e) NIR 
fluorescence image with QRH*-Cy5.5 shows the presence of flat lesions (arrowheads). (f) Image with Cy5.5-
control peptide shows minimal signal. Used with permission [49].
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CLE can be performed shortly following injection with its fluorescence lasting 
approximately 30 minutes. However, due to the lack of specificity of conventional 
contrast agents, there is an increasing use of tissue-specific binding molecular 
probes in CLE. The studies that used CLE in combination with a targeting peptide 
derived from phage display are summarized below.
Hsiung et al. used an M13 phage library to identify peptides that would specifi-
cally bind dysplastic colonic mucosa from fresh human colonic biopsies [39]. A 
peptide (VRPMPLQ ) that bound to colonic dysplasia was identified, synthesized, 
and conjugated with fluorescein for in vivo testing in a pilot study in patients 
undergoing routine colonoscopy using a flexible-fibered confocal microscope. 
Fluorescence images and videos of bound topically administered peptide collected 
in vivo showed that the selected peptide bound more strongly to dysplastic colono-
cytes than to the adjacent normal mucosa in the same subject with 81% sensitivity 
and 82% specificity.
In another study, Qiu and team demonstrated vertical cross-sectional 
(XZ-plane) images of NIR fluorescence with a handheld dual-axis confocal 
endomicroscope that revealed a specific binding of a Cy5.5-labeled peptide 
(LTTHYKLGGGSK-Cy5.5) to premalignant colonic mucosa in mice [50]. This 
targeting peptide was selected using in vivo phage display technology in a CPC;Apc 
mouse model which developed adenomas spontaneously in the distal colon. NIR 
vertical cross-sectional fluorescence images of fresh mouse colonic mucosa dem-
onstrate histology-like imaging performance as shown in Figure 6. The peptide 
showed specific binding and distinguished premalignant colonic mucosa from 
normal mucosa.
Gastric cancer vessels may have many differentiating characteristics compared 
to normal vessels. However, identification of gastric cancer vascular endothelial 
cells is difficult. Co-culture of gastric cancer cells and vascular endothelial cells was 
suggested to simulate gastric solid tumor mass. In a study, GEBP11, a nine amino 
Figure 6. 
Vertical cross-sectional image of colonic dysplasia. (a) Chemical structure of LTTHYKL peptide with GGGSK 
linker and Cy5.5 fluorophore. (b) NIR fluorescence image from CPC; Apc mouse colon ex vivo shows vertically 
oriented dysplastic crypts. (c) The border between normal colonic mucosa and dysplasia shows increased 
contrast from specific binding of the LTT*-Cy5.5 peptide. (d) Corresponding histology (H&E), scale bar 
200 μm. Used with permission [50].
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acid vascular homing peptide, was screened and identified using Ph.D.C7C phage 
display peptide library kit panning against Co-HUVECS cells [51]. Liu et al. used 
FITC-GEBP11 to identify gastric cancer in mouse model [52]. A whole-body fluo-
rescent imaging was first used to screen for the strongest specific fluorescent signal 
in xenograft models after tail vein injection of FITC-GEBP11. A specific signal was 
observed in both subcutaneous and orthotopic xenograft models in vivo, whereas 
the group injected with FITC-URP, a control peptide, showed no fluorescent sig-
nals. In addition, neoplastic and nonneoplastic gastric mucosae obtained from the 
patients were incubated with FITC-GEBP11 or FITC-URP for 30 minutes and were 
scanned with CLE. A specific signal of GEBP11 was observed in 26/28 neoplastic 
human specimens and in 8/28 samples of nonneoplastic specimens (p < 0.01).
Sturm and team developed a peptide (ASYNYDA) that binds specifically to 
high-grade esophageal dysplasia and adenocarcinoma using phage display technol-
ogy [53]. After peptide specific binding validation in human esophageal cancer 
specimens, they applied peptide topically and performed confocal endomicroscopy 
in 25 patients. The targeting peptide showed 3.8-fold greater fluorescence intensity 
for esophageal neoplasia compared with Barrett’s esophagus and squamous epi-
thelium with high sensitivity and specificity. The peptide revealed no toxicity in 
animals or patients.
In a pilot study, Palma and team identified dysplasia lesions in ulcerative colitis 
(UC) patients using CLE and a fluorescently labeled peptide [54]. A phage-derived 
peptide (VRPMPLQ ) was synthesized and conjugated with fluorescein. Eleven sus-
pected dysplasia specimens were collected from nine UC patients. Specimens were 
stained with the peptide and subsequently inspected by CLE. The CLE images were 
correlated to histological results from specialists. The peptide showed a different 
pattern on dysplastic mucosa compared to nondysplastic lesions. However, due to 
several restrictions of this study, further studies on larger UC patients are required 
for systematic validation.
ErbB2 expression in early breast cancer can predict tumor aggressiveness and 
clinical outcomes in patients. Up to 30% of all breast cancers express ErbB2, also 
known as HER2. Immunohistochemistry is commonly used to evaluate ErbB2 
expression, but it has limitations due to tumor heterogeneity. Therefore, the use of a 
specific biomarker for ErbB2 is increasingly popular. One study used a NIR-labeled 
ErbB2 peptide and a handheld dual-axis CLE to detect in human xenograft breast 
tumors and human specimens [55]. As a result, they found significantly greater 
peptide binding to xenograft breast cancer in vivo and to human specimens of 
invasive ductal carcinoma that express ErbB2 ex vivo. From the data, a miniature 
dual-axis confocal fluorescence endomicroscope with ErbB2-specific peptide could 
be implemented to support future image-guided surgery.
5.5 Multimodality imaging
Radiation-induced pulmonary fibrosis (RIPF) is a serious side effect of radiation 
therapy, especially in lung and breast cancers. Computed tomography (CT) imag-
ing is currently utilized to identify and monitor RIPF. However, anatomical change 
interference is a major limitation of CT. Therefore, RIPF detection and observing 
techniques need to be improved. Collagen accumulation is common in fibrosis. In 
one study, a collagen-targeting peptide was fabricated to maximize the visualization 
of fibrosis using fluorescence endomicroscope imaging [37]. The probe showed 
moderate binding ability to collagen in a fibrosis in vitro binding assay and on lung 
tissue specimens. The probe showed a similar binding pattern on lung specimens 
compared to antibody. But its sensitivity was not as good as the collagen-binding 
antibody.
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In another study, Zhang and team evaluated the potential applicability of 
GEBP11 peptides in gastric cancer diagnosis and radiotherapy. They developed 
iodine 131-labeled GEBP11 peptides and derivatives [56]. The clinical potential of 
GEBP11 peptides was determined with multimodality imaging methods. Cerenkov 
and SPECT imaging showed significantly higher tumor uptake for 131I-2PEG-
(GEBP11)3 trimer compared to monomer. Higher tumor accumulation and better 
T/B ratio of 131I-2PEG-(GEBP11)3 trimer were observed. Treating with 
131I-2PEG-
(GEBP11)3 trimer exhibited a significant tumor growth suppression compared 
to control and monomer groups. The tumor volume and vasculature decreased 
significantly after treatment with 131I-2PEG-(GEBP11)3 trimer, resulting in pro-
longed survival time. In addition, 131I-2PEG-(GEBP11)3 trimer showed no signifi-
cant hepatic or renal toxicity. In conclusion, 131I-2PEG-(GEBP11)3 trimer could be a 
potential ligand used to identify gastric cancer and in antiangiogenic therapy.
6. Future prospects
The discovery and development of therapeutic drugs and diagnostic probes 
are a time-consuming, expensive, and complex process. The processes involve 
experts from a wide range of disciplines such as medicinal chemistry, biochemistry, 
molecular biology, medicine, and pharmacology. It has been estimated that from 
about 10,000 new chemical entities identified, only one will reach the market in an 
average time of 16 years. Phage display, and particularly peptide phage display, has 
played a major role in the development pipeline for bringing peptide therapeutics 
into the clinic. Phage-derived peptides play an important role in disease detection 
and therapy, including in clinical imaging. The potential of peptides in preclinical 
and clinical molecular imaging is tremendous. Molecular imaging offers invalu-
able opportunities to explore complex disease-related biological processes at the 
molecular level in vivo. The emergence of current molecular imaging technologies is 
dependent not only on the progress of imaging systems but, more importantly, also 
on molecular imaging probes. Peptide-based imaging has now become an estab-
lished approach in nuclear imaging, and its application is expanding to other imag-
ing modalities. Considering the emergence of novel library designs and innovative 
selection strategies, we are confident that phage-derived peptides will continue to 
be promising biomarkers for early cancer detection, in metabolic abnormalities, 
and in personalized medicine.
Bacteriophages - Perspectives and Future
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